Microinvasive breast cancer: ER, PR, and HER-2/neu status and clinical outcomes after breast-conserving therapy or mastectomy

Annals of Surgical Oncology

Volumn 20, Issue 3, 2013, Pages 811-818

  Margalit, Danielle N ^a   Sreedhara, Meera ^a   Chen, Yu Hui ^a   Catalano, Paul J ^a   Nguyen, Paul L ^a   Golshan, Mehra ^a   Overmoyer, Beth A ^a   Harris, Jay R ^a   Brock, Jane E ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER RADIOTHERAPY; CANCER RECURRENCE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MICROINVASIVE BREAST CARCINOMA; PARTIAL MASTECTOMY; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE METASTASIS; TREATMENT OUTCOME;

ADULT; AXILLA; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MASTECTOMY; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE;

EID: 84875218498     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2640-8     Document Type: Article

References (27)

1. American Cancer Society. AJCC cancer staging manual, 6th ed. New York: Springer-Verlag, 2002.
2. I de Mascarel G MacGrogan S Mathoulin-Pelissier I Soubeyran V Picot JM Coindre 2002 Breast ductal carcinoma in situ with microinvasion: a definition supported by a long-term study of 1248 serially sectioned ductal carcinomas Cancer. 94 2134 2142 12001109 10.1002/cncr.10451
3. NQ Mirza G Vlastos F Meric, et al. 2000 Ductal carcinoma-in situ: long-term results of breast-conserving therapy Ann Surg Oncol. 7 656 664 11034242 10.1007/s10434-000-0656-y 1:STN:280:DC%2BD3cvosFGrsA%3D%3D
4. RF Padmore B Fowble J Hoffman C Rosser A Hanlon AS Patchefsky 2000 Microinvasive breast carcinoma: clinicopathologic analysis of a single institution experience Cancer. 88 1403 1409 10717623 10.1002/(SICI)1097- 0142(20000315)88:6<1403::AID-CNCR18>3.0.CO;2-S 1:STN:280: DC%2BD3c7otlGhsQ%3D%3D
5. D Rosner WW Lane R Penetrante 1991 Ductal carcinoma in situ with microinvasion. A curable entity using surgery alone without need for adjuvant therapy Cancer. 67 1498 1503 1848153 10.1002/1097-0142(19910315)67:6<1498:: AID-CNCR2820670606>3.0.CO;2-I 1:STN:280:DyaK3M7lvF2itA%3D%3D
6. ME Schuh T Nemoto RB Penetrante D Rosner TL Dao 1986 Intraductal carcinoma. Analysis of presentation, pathologic findings, and outcome of disease Arch Surg. 121 1303 1307 3022676 10.1001/archsurg.1986.01400110095016 1:STN:280:DyaL2s%2FkvVWgsA%3D%3D
7. SA Silver FA Tavassoli 1998 Mammary ductal carcinoma in situ with microinvasion Cancer. 82 2382 2390 9635531 10.1002/(SICI)1097-0142(19980615)82: 12<2382::AID-CNCR12>3.0.CO;2-L 1:STN:280:DyaK1c3pslCmtg%3D%3D
8. LJ Solin BL Fowble IT Yeh, et al. 1992 Microinvasive ductal carcinoma of the breast treated with breast-conserving surgery and definitive irradiation Int J Radiat Oncol Biol Phys. 23 961 968 1322388 10.1016/0360-3016(92)90900-3 1:STN:280:DyaK38zkvVagsw%3D%3D
9. JH Wong KH Kopald DL Morton 1990 The impact of microinvasion on axillary node metastases and survival in patients with intraductal breast cancer Arch Surg. 125 1298 1301 2171453 10.1001/archsurg.1990.01410220082011 1:STN:280:DyaK3M%2FisVGmsA%3D%3D
10. RR Parikh BG Haffty D Lannin MS Moran 2012 Ductal carcinoma in situ with microinvasion: prognostic implications, long-term outcomes, and role of axillary evaluation Int J Radiat Oncol Biol Phys. 82 7 13 20950955 10.1016/j.ijrobp. 2010.08.027
11. CC Vieira CL Mercado JF Cangiarella L Moy HK Toth AA Guth 2010 Microinvasive ductal carcinoma in situ: clinical presentation, imaging features, pathologic findings, and outcome Eur J Radiol. 73 102 107 19026501 10.1016/j.ejrad.2008.09.037
12. JH Kwon YJ Kim KW Lee, et al. 2010 Triple negativity and young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1 cm or less BMC Cancer. 10 557 20946688 10.1186/1471-2407-10-557
13. M Kyndi FB Sorensen H Knudsen M Overgaard HM Nielsen J Overgaard 2008 Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group J Clin Oncol. 26 1419 1426 18285604 10.1200/JCO.2007.14.5565 1:CAS:528:DC%2BD1cXkslKqs7c%3D
14. PL Nguyen AG Taghian MS Katz, et al. 2008 Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy J Clin Oncol. 26 2373 2378 18413639 10.1200/JCO.2007.14.4287
15. JM Albert AM Gonzalez-Angulo M Guray, et al. 2010 Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a, bN0 breast cancer Int J Radiat Oncol Biol Phys. 77 1296 1302 20472353 10.1016/j.ijrobp.2009.12.011 1:CAS:528:DC%2BC3cXovFCjur0%3D
16. AM Gonzalez-Angulo JK Litton KR Broglio, et al. 2009 High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller J Clin Oncol. 27 5700 5706 19884543 10.1200/JCO.2009.23.2025
17. LM Halasz M Sreedhara YH Chen, et al. 2012 Improved outcomes of breast-conserving therapy for patients with ductal carcinoma in situ Int J Radiat Oncol Biol Phys. 82 e581 e586 22208975 10.1016/j.ijrobp.2011.08.015
18. K Kerlikowske AM Molinaro ML Gauthier, et al. 2010 Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis J Natl Cancer Inst. 102 627 637 20427430 10.1093/jnci/djq101 1:CAS:528: DC%2BC3cXlvVWqtrw%3D
19. R Stackievicz H Paran J Bernheim, et al. 2010 Prognostic significance of HER-2/neu expression in patients with ductal carcinoma in situ Isr Med Assoc J. 12 290 295 20929083
20. AA Guth C Mercado DF Roses F Darvishian B Singh JF Cangiarella 2008 Microinvasive breast cancer and the role of sentinel node biopsy: an institutional experience and review of the literature Breast J. 14 335 339 18537917 10.1111/j.1524-4741.2008.00594.x
21. M Intra S Zurrida F Maffini, et al. 2003 Sentinel lymph node metastasis in microinvasive breast cancer Ann Surg Oncol. 10 1160 1165 14654471 10.1245/ASO.2003.04.009
22. A Grin G Horne M Ennis FP O'Malley 2009 Measuring extent of ductal carcinoma in situ in breast excision specimens: a comparison of 4 methods Arch Pathol Lab Med. 133 31 37 19123733
23. EK Latta S Tjan RK Parkes FP O'Malley 2002 The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast Mod Pathol. 15 1318 1325 12481013 10.1097/01.MP.0000038462.62634.B1 1:STN:280:DC%2BD38jhvVyhsg%3D%3D
24. K Park S Han HJ Kim J Kim E Shin 2006 HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry Histopathology. 48 702 707 16681686 10.1111/j.1365-2559. 2006.02403.x 1:STN:280:DC%2BD283lslOqtA%3D%3D
25. G Zavagno V Belardinelli R Marconato, et al. 2007 Sentinel lymph node metastasis from mammary ductal carcinoma in situ with microinvasion Breast. 16 146 151 17046258 10.1016/j.breast.2006.08.002
26. AC Wolff ME Hammond JN Schwartz, et al. 2007 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol. 25 118 145 17159189 10.1200/JCO.2006.09.2775 1:CAS:528:DC%2BD2sXht1ejs7Y%3D
27. H Yaziji LC Goldstein TS Barry, et al. 2004 HER-2 testing in breast cancer using parallel tissue-based methods JAMA. 291 1972 1977 15113815 10.1001/jama.291.16.1972 1:CAS:528:DC%2BD2cXjs1ajtrk%3D